BOSTON and LACEY, Wash., April 6 /PRNewswire/ -- AdipoGenix Inc. and
Unigen Pharmaceuticals, Inc. today announced that they have entered into an
agreement for the joint discovery and development of natural products that
target human fat. AdipoGenix is a biopharmaceutical company developing small
molecule therapies for obesity, type 2 diabetes and associated morbidities,
and Unigen is a leading natural products research and development facility and
supplier of proprietary, biologically active plant-derived ingredients to the
natural products and pharmaceutical industries.
Under the terms of the agreement, AdipoGenix and Unigen will equally share
in the costs and profits for the discovery, development, and commercialization
of products resulting from the collaboration. AdipoGenix will apply its
proprietary human fat cell-based technologies to discover natural substances
that reduce the fat content of human fat cells from Unigen's collection of
medicinal plant extracts. Unigen will identify and produce active molecules
from active extracts that are discovered and AdipoGenix will characterize
mechanisms of action and molecular targets for active molecules taken into
development. AdipoGenix will retain world wide rights for the development and
commercialization of any pharmaceutical products, and Unigen will retain world
wide rights for the commercialization of any cosmeceutical or nutraceutical
products that result from the collaboration. Additional terms were not
disclosed.
"AdipoGenix has a very promising approach to discovering new therapeutics
for obesity with their human fat cell-based technology. We believe that this
collaboration is a tremendous opportunity to develop novel plant-derived
products that address this important health concern," said Regan Miles,
Unigen's President and Chief Operating Officer. "This is an important part of
our strategy to expand our offerings in the large and growing market for
natural weight control products."
"Unigen has an extensive collection of extracts from medicinal plants from
around the world. Through this collaboration, we gain access to a unique
source of natural substances, and expand our opportunities to discover and
develop novel pharmaceuticals that reduce the fat content of human fat cells,"
said Ed Cannon, Ph.D., CEO of AdipoGenix. "Furthermore, we are pleased to
have in Unigen, a partner that allows us to leverage our proprietary human fat
cell-based technologies into the $25-plus billion market for nutraceuticals
and cosmeceuticals."
About Unigen Pharmaceuticals, Inc.
Unigen Pharmaceuticals, Inc. (http://www.UnigenPharma.com) is a leading
natural products research and development company and proprietary ingredients
supplier. The company is dedicated to the discovery of botanically derived
therapeutic compounds that address consumer health needs and help improve the
quality of human life. Its research and discovery process includes extensive
work at both the human cell and gene level. Unigen and sister company
Aloecorp, Inc. each focus on identifying and studying the unique ingredients
of medicinal botanicals (Aloecorp's focus is on Aloe vera) and then
formulating proprietary, patented raw materials for use in cosmeceutical,
nutraceutical and pharmaceutical products.
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing
pharmaceuticals that target human fat tissue to treat obesity and its
co-morbidities, including diabetes and cardiovascular disease. Through its
proprietary human fat cell-based technology, AdipoGenix identifies nontoxic,
small molecule compounds that reduce the fat content in human fat tissue,
which is expected to provide therapeutic benefit for these important diseases.
On the Net: http://www.AdipoGenix.com
http://unigenpharma.com
Contacts:
For AdipoGenix:
Ed Cannon Kari Watson
President and CEO MacDougall Biomedical Communications
AdipoGenix Inc. (508) 647-0209
617-638-6394 kwatson@macbiocom.com
For Unigen:
Regan Miles Qi Jia
President and COO Chief Scientific Officer
Unigen Pharmaceuticals Inc. Unigen Pharmaceuticals Inc.
360-486-8200 360-486-8200
reganmiles@earthlink.net qij@upi1.com
SOURCE AdipoGenix Inc.
 back to top
Related links:
http://www.AdipoGenix.com
http://unigenpharma.com
CONTACT:
Ed Cannon, President and CEO of AdipoGenix
Inc., +1-617-638-6394; or Kari Watson of MacDougall Biomedical
Communications, +1-508-647-0209, kwatson@macbiocom.com; or Regan
Miles, President and COO, reganmiles@earthlink.net, or Qi Jia,
Chief Scientific Officer, qij@upi1.com both of Unigen
Pharmaceuticals Inc., +1-360-486-8200
|
